Company Encyclopedia
View More
name
Sunshine Guojian Pharmaceutical
688336.SH
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company was founded in 2002 and is based in Shanghai, China.
1.601 T
688336.SHMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
B
BiotechnologyIndustry
Industry Ranking2/79
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE15.87%A
    • Profit Margin63.52%A
    • Gross Margin85.78%A
  • Growth ScoreB
    • Revenue YoY12.05%B
    • Net Profit YoY139.28%A
    • Total Assets YoY48.89%A
    • Net Assets YoY16.11%A
  • Cash ScoreC
    • Cash Flow Margin157.42%C
    • OCF YoY12.05%B
  • Operating ScoreD
    • Turnover0.19D
  • Debt ScoreB
    • Gearing Ratio33.51%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sunshine Guojian Pharmaceutical: Pfizer has registered two global Phase III clinical trials for the PD-1/VEGF dual antibody PF-08634404 (SSGJ-707) on a certain website, and the final payment remains uncertain

    Sunshine Guojian Pharmaceutical announced that the company has signed an exclusive development, production, and commercialization licensing agreement with Pfizer for the PD-1/VEGF bispecific antibody product 707. The agreement will take effect on July 24, 2025, and Pfizer has registered two global Phase III clinical trials on ClinicalTrials.gov. However, due to milestone payments being subject to specific conditions, there is uncertainty regarding the final payment, and investors should be aware of the risks

    Zhitong·
    SH
    688336
    -5.70%
    Zhitong·
    SH
    688336
    -5.70%

    A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suit

    Zhitong·
    SZ
    300878
    -2.07%
    SZ
    300497
    +14.01%
    SZ
    002940
    -3.97%
    Zhitong·
    SZ
    300878
    -2.07%
    SZ
    300497
    +14.01%
    SZ
    002940
    -3.97%